Sarcoidosis 相关的肺高血压
Yoshitaka Morimatsu1, Nobuhiro Tahara2, Masaki Okamoto3,4
1Department of Environmental Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
Medicina (Kaunas, Lithuania)
|February 26, 2025
概括
麻症相关的肺高血压 (SAPH) 是一种严重的并发症,影响多个器官. 虽然其确切的患病率和原因尚不清楚,但向疗法在改善患者的治疗结果方面显示出希望.
科学领域:
- 肺部病理学 肺部病理学
- 心脏病学 心脏病学
- 类风湿病学 类风湿病学
背景情况:
- Sarcoidosis是一种多系统颗粒状疾病,原因不明.
- 肺高血压 (PH) 是一种被认可的类菌病并发症,增加了患者的发病率和死亡率.
- Sarcoidosis-associated PH (SAPH) 被归类为PH分类的第5组 (多种类型).
研究的目的:
- 审查当前对 Sarcoidosis 相关的肺高血压 (SAPH) 的理解.
- 突出SAPH的未知流行病学和不完全理解的病原体.
- 讨论SAPH的可变临床表现和管理挑战.
主要方法:
- 关于肉病和肺高血压的文献综述.
- 分析SAPH的分类和临床特征.
- 对SAPH目前和潜在的治疗策略的评估.
主要成果:
- 尽管如此,SAPH的流行病学和病原性仍然在很大程度上是未知的.
- SAPH的呈现是可变的,并不总是与肉类突症的严重程度相关.
- 对于SAPH没有确定的治疗算法,尽管肺移植是耐火病例的选择.
结论:
- SAPH是沙丘病的严重并发症,需要专家管理.
- 针对关键路径的肺动脉高血压特异性血管扩张剂显示了SAPH的潜在益处.
- 需要进一步的研究来澄清SAPH的流行病学,病原和最佳治疗策略.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
144
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
144
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
125
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
125
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
124
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
124
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
161
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
161
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
126
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
126
Pulmonary Tuberculosis II
209
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
209


